Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.862
-0.005 (-0.54%)
Nov 20, 2024, 4:00 PM EST - Market open
Carisma Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue | 20.27 | 14.92 | 9.83 | - | - |
Revenue Growth (YoY) | 41.13% | 51.71% | - | - | - |
Cost of Revenue | 63.51 | 74.13 | 56.62 | 34.39 | - |
Gross Profit | -43.24 | -59.21 | -46.78 | -34.39 | - |
Selling, General & Admin | 23.53 | 29.53 | 9.38 | 6.41 | 5.09 |
Research & Development | - | - | - | - | 23.29 |
Operating Expenses | 23.53 | 29.53 | 9.38 | 6.41 | 28.38 |
Operating Income | -66.77 | -88.73 | -56.16 | -40.79 | -28.38 |
Interest Expense | - | - | -3.15 | - | - |
Interest & Investment Income | 2.78 | 1.94 | - | 0.01 | 0.03 |
Other Non Operating Income (Expenses) | - | -0.08 | -1.92 | - | - |
Pretax Income | -64 | -86.88 | -61.23 | -40.78 | -28.35 |
Net Income | -63.8 | -86.88 | -61.23 | -40.78 | -28.35 |
Net Income to Common | -63.8 | -86.88 | -61.23 | -40.78 | -28.35 |
Shares Outstanding (Basic) | 41 | 34 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 41 | 34 | 2 | 1 | 1 |
Shares Change (YoY) | 71.70% | 1475.33% | 96.30% | 1.95% | - |
EPS (Basic) | -1.55 | -2.59 | -28.77 | -37.62 | -26.66 |
EPS (Diluted) | -1.55 | -2.59 | -28.77 | -37.62 | -26.66 |
Free Cash Flow | -68.35 | -82.31 | -9.78 | -39.2 | -27.45 |
Free Cash Flow Per Share | -1.66 | -2.46 | -4.59 | -36.16 | -25.82 |
Operating Margin | -329.46% | -594.75% | -571.10% | - | - |
Profit Margin | -314.78% | -582.34% | -622.60% | - | - |
Free Cash Flow Margin | -337.21% | -551.71% | -99.41% | - | - |
EBITDA | -63.37 | -85.89 | -54.27 | -40.11 | -27.93 |
D&A For EBITDA | 3.41 | 2.84 | 1.89 | 0.68 | 0.45 |
EBIT | -66.77 | -88.73 | -56.16 | -40.79 | -28.38 |
Source: S&P Capital IQ. Standard template.
Financial Sources.